Neurology
- Active ingredient (INN)
- piracetam
- Composition (active ingredients)
- piracetam - 400,0 mg
- Фармакотерапевтическая группа
- nootropic agent
- Pharmacotherapeutic group
- capsules 400 mg №60
- Сonditions of supply
- on prescription
Indications
- symptomatic treatment of intellectual-mnestic disorders in the absence of an established diagnosis of dementia;
- a decrease in the manifestations of cortical myoclonus in patients sensitive to piracetam, both as monotherapy and as part of complex therapy (in order to determine the sensitivity to piracetam in a particular case, a trial course of treatment can be carried out).
Dosage regimen
Inside, during meals or on an empty stomach. Capsules are swallowed without chewing, washed down with water. If oral administration is impossible, the drug is administered intravenously at the same dose.
- With intellectual and mnestic disorders
-
2,4-4,8 g/day (6-12 capsules per day) in 2-3 doses
- Treatment of cortical myoclonus
-
start with a dose of 7,2 g per day (18 capsules per day), increasing it by 4,8 g (12 capsules) every 3-4 days to a maximum dose of 24 g per day (60 capsules), divided into 2-3 doses
The dose of other drugs for the treatment of myoclonus is not changed. In the future, according to the results of treatment, it is necessary, if possible, to reduce the dose of other drugs for the treatment of myoclonus.
After starting treatment with piracetam, treatment is continued as long as symptoms of the disease persist.
In patients with acute episodes of myoclonus, spontaneous improvement may occur, therefore, attempts should be made every 6 months to reduce the dose or discontinue the drug. To do this, gradually reduce the dose by 1,2 g per day (3 capsules) every 2 days (in order to prevent the possibility of a sudden relapse or withdrawal syndrome in Lance-Adams syndrome - every 3-4 days).
Renal failure:
Piracetam is excreted almost exclusively by the kidneys; caution should be exercised when treating patients with renal insufficiency or requiring monitoring of renal function.
The half-life increases in direct proportion to the deterioration in renal function and creatinine clearance; this is also true for the elderly, in whom the excretion of creatinine is dependent on age.
The dose of piracetam should be adjusted depending on the creatinine clearance (CC).
Liver failure:
Patients with impaired liver function do not need dose adjustment.
